WO2004028502A1 - 抗真菌剤および抗細菌剤配合洗浄用組成物 - Google Patents
抗真菌剤および抗細菌剤配合洗浄用組成物 Download PDFInfo
- Publication number
- WO2004028502A1 WO2004028502A1 PCT/JP2003/012325 JP0312325W WO2004028502A1 WO 2004028502 A1 WO2004028502 A1 WO 2004028502A1 JP 0312325 W JP0312325 W JP 0312325W WO 2004028502 A1 WO2004028502 A1 WO 2004028502A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- agent
- antibacterial
- bacteria
- antifungal
- stone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
- A01N43/50—1,3-Diazoles; Hydrogenated 1,3-diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
Definitions
- the present invention relates to a cleaning composition for pharmaceuticals, quasi-drugs or cosmetics, which has a broad antibacterial and antifungal spectrum and is excellent in efficacy and safety.
- the most common method of daily hand washing is with stones and running water, which is the physical removal of dirt, organic matter and transient microorganisms (bacteria, fungi, viruses, etc.) from the hands. .
- the bactericidal effect of bacteria that have been artificially attached to hands depends on the time of hand washing, and the amount of bacteria is 1/10 in 15 seconds of hand washing. It has been reported that 1Z100 in 30 seconds and 11000 in more than 1 minute. In other words, by washing with ordinary stone stones and running water for 1 minute or more, the attached bacteria can be sufficiently removed.
- antibacterial agent-containing stones for increasing the disinfection efficiency during washing are commercially available. Used by workers in food production and medical facilities, where bacterial infection is particularly important, to prevent food poisoning, disinfect and disinfect bacteria from the environment that adhere to soil or pets, etc. In addition, cleaning with antibacterial agent-containing stones in ordinary households is becoming commonplace.
- an antibacterial agent-containing stone an antibacterial agent-containing stone containing triclosan, triclocarban and an antibacterial agent such as Z or isopropylmethylphenol is commercially available.
- compositions containing an antifungal agent for preventing dandruff are known.
- an anti-dandruff agent containing miconazole or its nitrate which has a strong antifungal effect against fungi and ora / e (Japanese Patent Application Laid-Open No. 8-3042).
- the inhibitor used herein is, for example, shampoo for preventing dandruff caused by P. ovale, but the inhibitor does not contain the antibacterial agent as described above.
- compositions containing one or more antibacterial and antifungal agents and phospholipids that inhibit the biosynthesis of fungi and mold ergosterol (Table 2) Report).
- azole which is an antifungal agent is exemplified as an antibacterial and antifungal agent, and a compound known as an antibacterial agent is not exemplified.
- the bacteria in this document substantially means fungi and do not include antibacterial agents.
- Some actives along with certain surfactants, disclose foaming cleansing creams for greasy or acne-prone skin that include antiseborrheic actives and Z or antimicrobial agents.
- Japanese Patent Application Laid-Open No. 2002-14045 736 discloses foaming cleansing creams for greasy or acne-prone skin that include antiseborrheic actives and Z or antimicrobial agents.
- Japanese Patent Application Laid-Open No. 2002-14045 736 disclose foaming cleansing creams for greasy or acne-prone skin that include antiseborrheic actives and Z or antimicrobial agents.
- a fungicide composition having a skin-protecting effect containing a complex of a fungicide and a water-swellable viscosity mineral has also been proposed (Japanese Patent Application Laid-Open No. 10-265408).
- fungicides Antibacterial agents such as triclosan and isopropylmethylphenol, azolic antifungal agents and the like are described.
- the document states that when a fungicide is used in a complex with the above viscous mineral, the antibacterial activity is persistent, and that one or more fungicides are arbitrarily selected.
- the examples exemplified for each application show the sustained effect when one kind of drug corresponding to each application is formed into a complex with the above-mentioned viscous mineral.
- fungi attached to the hands can enter the body orally, causing fungal infections in various organs.
- Fungi are also considered as one of the causes (allergens) of allergic diseases, and C. albicans is regarded as important in relation to atopic dermatitis as an allergic skin disease. .
- the present inventors have recognized the need for a cleaning composition having a broad antibacterial and antifungal spectrum.
- the inventor of the present invention in the process of variously examining a cleaning composition containing an antifungal agent and an antibacterial agent, found that among the antifungal agents, this was used as a normal antibacterial stone. It was found that there is a problem that even if it is blended as it is, its solubility, effect, stability, and the like vary greatly, and it is difficult to obtain a stable cleaning composition.
- antifungals, antibacterials, and cleaning ingredients have a skin irritating effect, and their effects (antifungal, antibacterial, cleaning, It is also necessary to balance the balance between antibacterial agents and residual effects of antifungal agents) and safety (less skin irritation). Disclosure of the invention
- the present invention solves these problems and provides a cleaning composition containing an antifungal agent and an antibacterial agent, particularly a cleaning composition that can be used for pharmaceuticals, quasi-drugs, or cosmetics. It has a wide spectrum of antibacterial and antifungal properties, is stable and has excellent usability, has excellent detergency, has little skin irritation, and has the effect of preventing itching and deodorizing of the scalp and body.
- An object of the present invention is to provide a cleaning composition capable of preventing infectious diseases caused by shampoo.
- the present inventors have conducted intensive studies on a cleaning composition containing an antifungal agent and an antibacterial agent, and found that a cleaning composition containing an azole-based antifungal agent and an antibacterial agent has a strong and broad It has an antibacterial and antifungal spectrum, the product itself is stable, it has excellent usability, it has excellent detergency, it does not cause skin irritation or other adverse events, and it can prevent itching and deodorant effects on the scalp and body.
- the present inventors have found that at least one of the above-mentioned problems can be solved, such as an effect of preventing infectious diseases caused by indigenous bacteria and passing bacteria, and thus completed the present invention.
- a cleaning composition for a pharmaceutical, a quasi-drug, or a cosmetic which contains an azole antifungal agent and an antibacterial agent.
- the antifungal agent is preferably miconazole and / or a salt thereof.
- the antibacterial agent is preferably at least one selected from triclosan, triclocarban and isopropylmethylphenol.
- a cleaning composition in which the antifungal agent is miconazole nitrate and the antibacterial agent is Tricsan is a preferred embodiment of the present invention.
- the content of the antifungal agent is 0.1 to 2.0 wt%, and the content of the antibacterial agent is 0.01 to 1.5 wt%. It is.
- the cleaning composition of the present invention may contain a mild surfactant as a cleaning component.
- the washing and cleaning composition of the present invention is provided, for example, in the form of stone.
- FIG. 1 is a graph showing the results of a bacterial test in Example 5, showing the cleaning effect of the stone of the present invention in comparison with a control stone.
- FIG. 2 is a graph showing the results of a fungal test in Example 5, showing the cleaning effect of the stone of the present invention in comparison with a control stone.
- the present invention is an antifungal 'antibacterial cleaning composition for pharmaceuticals, quasi-drugs or cosmetics, having a broad antifungal and antibacterial spectrum.
- the cleaning composition of the present invention contains an antifungal agent and an antibacterial agent as essential components, and is characterized by containing an azole antifungal agent as the antifungal agent.
- Examples of the azolic antifungal agent in the present invention include miconazole, clotrimazole, econazole, choconazole, oxiconazole, fluconazole, itraconazole, ketoconazole, croconazole, neticonconazole, and isoconazole.
- Examples of the salt include nitrate and hydrochloride, and preferably nitrate. In the present invention, two or more of these may be included in the cleaning composition.
- miconazole clotrimazole, econazole, choconazole, oxyconazole, sulconazole, bifonazole and their salts are preferred, and miconazole nitrate is more preferred. It is.
- the above-mentioned miconazole and miconazole nitrate mean a compound having a structure represented by the following (I) and ( ⁇ ).
- the above azole antifungal agent is available as a commercial product.
- the antibacterial agent used in the present invention is not particularly limited as long as it has a growth inhibitory effect on bacteria, but a diphenyl ether compound, a carbanilide compound or a phenol compound is preferable, and specifically, triclosan, triclocarban And isopropylmethylphenol. Among them, Trik mouth sun is preferred.
- antibacterial agents are available as commercial products.
- a particularly preferred embodiment of the present invention is the combination, wherein the antifungal agent is miconazole nitrate and the antibacterial agent is Tricsan.
- the amount of the antifungal agent and the antibacterial agent in the composition is not particularly limited, but is usually
- the compounding amount of the antifungal agent is 0.1 to 2.0%, and the compounding amount of the antibacterial agent is 0.0 :! ⁇ 1.5 wt%.
- the amount is preferably 0.1 to 1.0 wt%, and when the antibacterial agent is triclosan, the amount is 0.05 to 0.5 wt%. 1.0% is preferred.
- the cleaning component to be added to the cleaning composition is not particularly limited as long as the cleaning component does not impair the efficacy of the antifungal agent and the antibacterial agent, and may include an anionic surfactant.
- anionic surfactants such as alkyl sulfate sodium salt, amphoteric surfactants such as alkyl dimethyl ammonium betaine, and nonionic surfactants such as polyoxyethylene alkyl ether Surfactants and the like can be used in appropriate combination.
- These surfactants are preferably low irritants, and examples of low irritant anionic surfactants include monoalkyl phosphates, acyl glutamates, acyl methyl taurates, cocoyl isethionates, Lauroyl-methyl
- Examples of the low-irritating amphoteric surfactant include betaine-type amphoteric surfactants such as 2-alkyl-1-N-carboxymethyl_N-hydroxy. And ethyl imidazolidine betaine.
- a combination of a mildly anionic surfactant and a mildly amphoteric surfactant is preferred.
- the cleaning composition of the present invention further includes components used in ordinary cleaning compositions, for example, humectants such as propylene glycol and glycerin, conditioning components such as cationic polymers, coloring agents such as pigments and pigments, Viscosity modifiers such as methylcellulose and polyethylene glycol, pH regulators such as citric acid and potassium oxide, salts such as sodium chloride, plant extracts, preservatives, vitamins, fragrances, ultraviolet absorbers, antioxidants , Water and the like can be appropriately added.
- humectants such as propylene glycol and glycerin
- conditioning components such as cationic polymers
- coloring agents such as pigments and pigments
- Viscosity modifiers such as methylcellulose and polyethylene glycol
- pH regulators such as citric acid and potassium oxide
- salts such as sodium chloride
- plant extracts such as preservatives
- vitamins, fragrances, ultraviolet absorbers, antioxidants , Water and the like can be appropriately added.
- cleaning composition refers to a composition in which a cleaning component is blended, and after use, is washed away with running water or the like.
- the form is not particularly limited, stone (solid stone, liquid stone, foamed stone, body soap, hand soap, etc.), cleansing foam, shampoo (hair shampoo, dry shampoo, etc.) And the like. Of these, stones are preferred, and liquid stones and body soaps are particularly preferred. Examples of the cleaning composition of the present invention are shown below, but the present invention is not limited thereto.
- test drug was dissolved in DMSO, and miconazole was adjusted to 102,400 Mg / mL (titer) and triclosan was adjusted to 409,600 ⁇ g / mL (titer).
- the miconazole solution prepared at 102, 400 / mL (titer) was further prepared in a two-fold dilution series using DMS0 to prepare 102, 400 to 50 wgZmL (titer).
- Triclosan drug solution adjusted to 409, 600 M g / mL (titer) was further prepared in a 2-fold dilution series using DMSO, and adjusted to 409, 600 to 6.00 g / mL (titer). .
- the inoculum was inoculated into each well at 5 / L, and the amount of bacteria in the drug-free medium used as a target was measured to determine the amount of inoculated bacteria.
- the minimum drug concentration in the tube where growth of the bacteria was not visually observed was defined as MIC.
- C. albicans was cultured on Sabouraud dextrose agar medium (BBL) at 35 ° C. for 24 to 48 hours, and then adjusted to McFarland ⁇ .5 with sterile physiological saline. It was diluted 1000-fold with RPMI 1640 medium containing 0.165 mol / L MOPS to obtain a test bacterial solution (1 to 5 ⁇ 10 3 cells / mL).
- T. rubrum was modified 2% on a modified 1Z10 Sabouraud glucose agar slant. Then, after culturing for 1 to 2 weeks, sterile physiological saline solution containing 0.1% Tween 80 was added, conidia were collected, and the conidia were filtered with sterile gauze. The conidia suspension was further diluted with sterile physiological saline containing 0.1% Tween 80, and the number of bacteria was adjusted to 10 6 cellsZmL using a hemocytometer to obtain a test bacterial solution.
- the drug to be measured was dissolved in DMSO and adjusted to 12,800 Mg / mL (titer) for each of miconazole and triclosan.
- the miconazole and triclosan drug solutions prepared at 12,800 / xg / mL (titer) were further prepared in 2-fold dilution series using DMSO to obtain 12,800-60 g / mL (titer). It was adjusted.
- the minimum drug concentration in the tube where growth of the bacteria was not visually observed was defined as MIC.
- evaluation MIC value (g / mL)
- Example 2 The liquid stone prepared in Example 2 was a clear, slightly yellow liquid immediately after preparation, and no insolubles were observed. In addition, this liquid stone was stored in a plastic container for 6 months at a temperature of 40 ° C and a relative humidity of 75%. As a result, the residual ratio of miconazole nitrate and triclosan was 95% or more in each case. Quantified by the usual method used), and no precipitation, coloring, etc. were observed. (Example 4) Use of liquid stone (1)
- the liquid stone prepared in Example 2 was hand-washed and used for the whole body according to a conventional method. Uncomfortable feeling during and after washing, tingling of skin, and bulkiness of skin are observed. It had excellent usability.
- stamp-stamp medium commercially available SCDLP agar medium; containing soybean casein hydrolyzate, lecithin and polysorbate 80
- Example 2 Liquid stone prepared in Example 2 diluted to 7% and placed in a foam ejection container (invention stone) and liquid stone prepared by removing miconazole nitrate from the composition of Example 2 (control stone) ), The subject's right and left palms were washed with one hand for a certain period of time.
- Washing was carried out by each person in charge of the present invention stones and the control stones, washing the hands of all subjects randomly under the blinds, left and right randomly (2 pushes for 5 seconds). .
- Washing was carried out by the person in charge of the stone of the present invention and the control stone by washing the feet of all subjects randomly under the blind, left and right with a fixed method (2 pushes for 5 seconds). .
- Inoculated bacterial solution was inoculated into each well in an amount of 5 L, and the amount of bacteria in the drug-free medium used as a control was measured to determine the amount of inoculated bacteria.
- the minimum drug concentration in the tube where growth of the bacteria was not visually observed was defined as MIC.
- C. albicans was cultured on Sabouraud dextrose agar medium (88) at 35 ° (:, 48 hours), and then prepared with sterile physiological saline to McFarland No. 0.5. It was diluted 1000-fold with RPMI 1640 medium containing mol / L MOPS to obtain a test bacterial solution (1 to 5 ⁇ 10 3 cells ZmL).
- T. rubrwn was cultured on a modified 1/10 sub-oral glucose agar slant medium for 271 weeks and then added with 0.1% Tween n80 in sterile physiological saline to collect conidia and filtered through sterile gauze. .
- the conidia suspension was further diluted with RPMI 1640 medium containing 0.165 mol / L MOPS, and the number of bacteria was adjusted to 10 6 cells / mL using a hemocytometer to obtain a test bacterial solution.
- the measurement medium prepared in (3) was dispensed in 100 L portions. As a control, 100 L of drug-free medium was dispensed. (5) Inoculate 100 L of the bacterial solution prepared in (1), C. albicans at 35 ° C for 48 hours, and T. rubrim at 21. And cultured for 1 week.
- Triclosan 0.30 g Miconazole nitrate 0.75 g N-coconut oil fatty acid acyl-L-potassium monoglutamate 5.00 g
- Triclocarban 0.50 g Miconazole nitrate 0.75 g
- the cleaning composition of the present invention for a novel drug, quasi-drug, or cosmetic, which contains an antifungal agent and an antibacterial agent.
- cleaning compositions containing an azole antifungal agent and an antibacterial agent as antifungal agents have a strong and broad antibacterial and antifungal spectrum, are stable in the product itself, and have excellent usability. Excellent detergency, no adverse effects such as skin irritation, prevention of scalp and body itch and deodorization effects, prevention of infectious diseases caused by resident bacteria and passing bacteria It has at least one excellent property.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Pest Control & Pesticides (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Agronomy & Crop Science (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Detergent Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004539553A JPWO2004028502A1 (ja) | 2002-09-27 | 2003-09-26 | 抗真菌剤および抗細菌剤配合洗浄用組成物 |
AU2003266643A AU2003266643A1 (en) | 2002-09-27 | 2003-09-26 | Cleansing composition containing antifungal agent and antibacterial agent |
KR1020057003311A KR101045867B1 (ko) | 2002-09-27 | 2003-09-26 | 항진균제 및 항세균제 배합 세정용 조성물 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002283651 | 2002-09-27 | ||
JP2002/283651 | 2002-09-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004028502A1 true WO2004028502A1 (ja) | 2004-04-08 |
Family
ID=32040564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/012325 WO2004028502A1 (ja) | 2002-09-27 | 2003-09-26 | 抗真菌剤および抗細菌剤配合洗浄用組成物 |
Country Status (5)
Country | Link |
---|---|
JP (1) | JPWO2004028502A1 (ja) |
KR (1) | KR101045867B1 (ja) |
CN (1) | CN100370965C (ja) |
AU (1) | AU2003266643A1 (ja) |
WO (1) | WO2004028502A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008540581A (ja) * | 2005-05-16 | 2008-11-20 | ノヴァファーム リサーチ (オーストラリア) ピーティーワイ リミテッド | 外科手術に向けた患者の準備に使用するための方法および組成物 |
JP2010275198A (ja) * | 2009-05-26 | 2010-12-09 | Mochida Pharmaceut Co Ltd | 洗浄用組成物 |
WO2012177986A2 (en) | 2011-06-22 | 2012-12-27 | Vyome Biosciences | Conjugate-based antifungal and antibacterial prodrugs |
WO2014195872A1 (en) | 2013-06-04 | 2014-12-11 | Vyome Biosciences Pvt. Ltd. | Coated particles and compositions comprising same |
JP2015168615A (ja) * | 2014-03-04 | 2015-09-28 | 持田製薬株式会社 | 洗浄用組成物 |
WO2018199303A1 (ja) * | 2017-04-28 | 2018-11-01 | 持田製薬株式会社 | ミコナゾール及び/又は硝酸ミコナゾールを含むシート製剤 |
JP2019081763A (ja) * | 2018-12-27 | 2019-05-30 | 持田製薬株式会社 | 洗浄用組成物 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102226135A (zh) * | 2011-05-12 | 2011-10-26 | 荆立民 | 杀菌去污除臭洗鞋液及其制备方法 |
KR102089397B1 (ko) | 2018-03-02 | 2020-03-16 | 충북대학교 산학협력단 | 미코나졸을 유효성분으로 포함하는 퇴행성 중추신경계 질환의 예방 또는 치료용 약학 조성물 |
KR102089411B1 (ko) | 2020-02-27 | 2020-03-16 | 충북대학교 산학협력단 | 미코나졸을 유효성분으로 포함하는 퇴행성 중추신경계 질환의 예방 또는 치료용 약학 조성물 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0520873A1 (fr) * | 1991-06-24 | 1992-12-30 | L'oreal | Composés alkylthiopoly(éthylimidazolium), procédé de préparation et leur utilisation comme agents biocides |
EP0680745A2 (fr) * | 1994-05-05 | 1995-11-08 | L'oreal | Utilisation de composés antifongiques et de composés antibactériens halogénés pour diminuer la chute des cheveux |
WO1997022346A2 (de) * | 1995-12-16 | 1997-06-26 | Beiersdorf Ag | Verwendung von zuckerderivaten als antimikrobiell, antimykotisch und/oder antivirale wirkstoffe |
JPH09176014A (ja) * | 1995-12-26 | 1997-07-08 | Taiho Yakuhin Kogyo Kk | 抗真菌性外用組成物 |
JPH10265408A (ja) * | 1997-03-25 | 1998-10-06 | Lion Corp | 殺菌剤組成物 |
JP2003063984A (ja) * | 2001-06-26 | 2003-03-05 | L'oreal Sa | N−アシルアミノアミドファミリーのエラスターゼ阻害剤と少なくとも1種の抗真菌剤又は少なくとも1種の抗菌剤の組み合わせを含む化粧品用又は皮膚用組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2798847B1 (fr) * | 1999-09-29 | 2001-11-23 | Oreal | Composition de traitement antipelliculaire des cheveux et du cuir chevelu, a base d'un agent antipelliculaire et d'un terpolymere acrylique |
US7074392B1 (en) * | 2000-03-27 | 2006-07-11 | Taro Pharmaceutical Industries Limited | Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections |
JP5217450B2 (ja) | 2008-01-24 | 2013-06-19 | 沖電気工業株式会社 | 自動取引システムおよび自動取引装置 |
-
2003
- 2003-09-26 JP JP2004539553A patent/JPWO2004028502A1/ja not_active Withdrawn
- 2003-09-26 KR KR1020057003311A patent/KR101045867B1/ko active IP Right Grant
- 2003-09-26 WO PCT/JP2003/012325 patent/WO2004028502A1/ja active Application Filing
- 2003-09-26 CN CNB038231204A patent/CN100370965C/zh not_active Expired - Fee Related
- 2003-09-26 AU AU2003266643A patent/AU2003266643A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0520873A1 (fr) * | 1991-06-24 | 1992-12-30 | L'oreal | Composés alkylthiopoly(éthylimidazolium), procédé de préparation et leur utilisation comme agents biocides |
EP0680745A2 (fr) * | 1994-05-05 | 1995-11-08 | L'oreal | Utilisation de composés antifongiques et de composés antibactériens halogénés pour diminuer la chute des cheveux |
WO1997022346A2 (de) * | 1995-12-16 | 1997-06-26 | Beiersdorf Ag | Verwendung von zuckerderivaten als antimikrobiell, antimykotisch und/oder antivirale wirkstoffe |
JPH09176014A (ja) * | 1995-12-26 | 1997-07-08 | Taiho Yakuhin Kogyo Kk | 抗真菌性外用組成物 |
JPH10265408A (ja) * | 1997-03-25 | 1998-10-06 | Lion Corp | 殺菌剤組成物 |
JP2003063984A (ja) * | 2001-06-26 | 2003-03-05 | L'oreal Sa | N−アシルアミノアミドファミリーのエラスターゼ阻害剤と少なくとも1種の抗真菌剤又は少なくとも1種の抗菌剤の組み合わせを含む化粧品用又は皮膚用組成物 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008540581A (ja) * | 2005-05-16 | 2008-11-20 | ノヴァファーム リサーチ (オーストラリア) ピーティーワイ リミテッド | 外科手術に向けた患者の準備に使用するための方法および組成物 |
JP2013173758A (ja) * | 2005-05-16 | 2013-09-05 | Novapharm Research (Australia) Pty Ltd | 外科手術に向けた患者の準備に使用するための方法および組成物 |
KR101413138B1 (ko) | 2005-05-16 | 2014-07-01 | 노바팜 리서치(오스트레일리아)피티와이리미티드 | 환자의 수술 준비에 사용하기 위한 방법 및 조성물 |
US9511017B2 (en) | 2005-05-16 | 2016-12-06 | Novapharm Research (Australia) Pty Ltd | Method and composition for use in preparation of a patient for surgery |
JP2010275198A (ja) * | 2009-05-26 | 2010-12-09 | Mochida Pharmaceut Co Ltd | 洗浄用組成物 |
WO2012177986A2 (en) | 2011-06-22 | 2012-12-27 | Vyome Biosciences | Conjugate-based antifungal and antibacterial prodrugs |
WO2014195872A1 (en) | 2013-06-04 | 2014-12-11 | Vyome Biosciences Pvt. Ltd. | Coated particles and compositions comprising same |
JP2015168615A (ja) * | 2014-03-04 | 2015-09-28 | 持田製薬株式会社 | 洗浄用組成物 |
WO2018199303A1 (ja) * | 2017-04-28 | 2018-11-01 | 持田製薬株式会社 | ミコナゾール及び/又は硝酸ミコナゾールを含むシート製剤 |
JPWO2018199303A1 (ja) * | 2017-04-28 | 2020-05-14 | 持田製薬株式会社 | ミコナゾール及び/又は硝酸ミコナゾールを含むシート製剤 |
JP7030110B2 (ja) | 2017-04-28 | 2022-03-04 | 持田製薬株式会社 | ミコナゾール及び/又は硝酸ミコナゾールを含むシート製剤 |
JP2019081763A (ja) * | 2018-12-27 | 2019-05-30 | 持田製薬株式会社 | 洗浄用組成物 |
Also Published As
Publication number | Publication date |
---|---|
KR20050059141A (ko) | 2005-06-17 |
JPWO2004028502A1 (ja) | 2006-01-19 |
CN100370965C (zh) | 2008-02-27 |
KR101045867B1 (ko) | 2011-07-01 |
CN1684662A (zh) | 2005-10-19 |
AU2003266643A1 (en) | 2004-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bhargava et al. | Triclosan: applications and safety | |
EP1032263B1 (en) | Surfactant-based antimicrobial compositions and methods for using same | |
JPH11322591A (ja) | 防腐殺菌剤及び人体施用組成物 | |
EP2404502B1 (en) | Compositions containing pyrrolidone carboxylic acid (pca) and metallic salts | |
US20090226384A1 (en) | Antimicrobial composition containing triclosan and at least one functionalized hydrocarbon | |
JPH10510290A (ja) | 液体スキンクレンジング調合物 | |
US20110082118A1 (en) | Onychomycosis Treatment Delivery System | |
CN110113942A (zh) | 协同抗微生物组合物 | |
WO2004028502A1 (ja) | 抗真菌剤および抗細菌剤配合洗浄用組成物 | |
JP3603924B2 (ja) | 殺菌剤組成物 | |
JP2011074082A (ja) | 防腐殺菌剤及び人体施用組成物 | |
US20110076261A1 (en) | Antifungal Drug Delivery System | |
JP4255965B2 (ja) | 抗真菌剤および抗細菌剤配合洗浄用組成物 | |
JP2002510292A (ja) | 脂漏性皮膚炎、フケ、乾癬及びニキビを治療するジクロロフェニルイミダゾールジオキソランを含有する組成物の使用方法及び該組成物 | |
US11306054B2 (en) | Propanediol monoacetate mononitrate | |
JP2010270083A (ja) | 防腐剤組成物、その使用、その製造方法、およびそれを含有する製剤 | |
JP4734293B2 (ja) | 防腐殺菌剤及び人体施用組成物 | |
JP3385293B2 (ja) | アルトカルピン含有抗菌・防腐剤及び化粧料 | |
CN111065268B (zh) | 抗微生物组合物 | |
JP4953409B2 (ja) | 抗菌剤 | |
WO2003059297A2 (en) | Dermatological topical compositions and a process for the preparation thereof | |
JP2014088373A (ja) | ミコナゾール硝酸塩を含む洗浄用組成物 | |
JP2005132777A (ja) | 抗菌剤 | |
JP2003160450A (ja) | シャンプー組成物 | |
JP2003095852A (ja) | ソフォラフラバノンg含有抗菌剤及び化粧料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004539553 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057003311 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038231204 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057003311 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase |